Literature DB >> 30683924

Estimating the prevalence of allelic variants in the transthyretin gene by analysing large-scale sequencing data.

Carmen Lahuerta Pueyo1, Miguel Ángel Aibar Arregui2, Anyuli Gracia Gutierrez2, Esperanza Bueno Juana2, Sebastián Menao Guillén3.   

Abstract

Transthyretin amyloidosis (ATTR amyloidosis) is a rare disease characterised by extracellular deposition of amyloid fibrils composed by transthyretin. ATTR amyloidosis can be sub-classified as wild-type ATTR (ATTR-wt) or as hereditary amyloidosis (ATTR-m); the prevalence of both types are likely underestimated. There are tools that can help us to study ATTR-m, as gnomAD database. Our primary aim was to estimate prevalence of variants, especially amyloidogenic variants, in the TTR gene using gnomAD database. We analysed TTR missense variants found in gnomAD. The variables studied were classified according to their clinical significance and according to the different populations. We found 71 missense variants in the TTR gene. Eleven variants were described as affects function variants (prevalence 1:230). The most frequently detected variant were c.424G>A (p.(Val142Ile)) (prevalence 1:332, MAF 0.00151) and c.148G>A (p.(Val50Met)) (prevalence 1:4924, MAF 0.000102), which represented 88% and 5%, respectively, of all affects function variants detected. Seventeen variants were classified as probably affects function, 29 as unknown variants, 4 as probably does not affect function and 10 as does not affect function variants. In terms of different populations, c.424G>A (p.(Val142Ile)) was especially prevalent in African population (MAF 0.01602; prevalence of 1:31) and c.148G>A (p.(Val50Met)) in European population (MAF 0.000179; prevalence of 1:2792). Prevalence of amyloidogenic variants in the general population was higher than prevalence heretofore described. This difference could be explained by incomplete penetrance of the disease, but other factors contributing to this fact, fundamentally the underdiagnosis of the disease.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30683924      PMCID: PMC6461877          DOI: 10.1038/s41431-019-0337-1

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  8 in total

1.  Elderly patients with suspected Charcot-Marie-Tooth disease should be tested for the TTR gene for effective treatments.

Authors:  Takaki Taniguchi; Masahiro Ando; Yuji Okamoto; Akiko Yoshimura; Yujiro Higuchi; Akihiro Hashiguchi; Nozomu Matsuda; Mamoru Yamamoto; Eisuke Dohi; Makoto Takahashi; Masanao Yoshino; Taichi Nomura; Masaaki Matsushima; Ichiro Yabe; Yui Sanpei; Hiroyuki Ishiura; Jun Mitsui; Masanori Nakagawa; Shoji Tsuji; Hiroshi Takashima
Journal:  J Hum Genet       Date:  2022-01-14       Impact factor: 3.172

2.  Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis - 2021.

Authors:  Marcus V Simões; Fabio Fernandes; Fabiana G Marcondes-Braga; Philip Scheinberg; Edileide de Barros Correia; Luis Eduardo P Rohde; Fernando Bacal; Silvia Marinho Martins Alves; Sandrigo Mangini; Andréia Biolo; Luis Beck-da-Silva; Roberta Shcolnik Szor; Wilson Marques Junior; Acary Souza Bulle Oliveira; Márcia Waddington Cruz; Bruno Vaz Kerges Bueno; Ludhmila Abrahão Hajjar; Aurora Felice Castro Issa; Felix José Alvarez Ramires; Otavio Rizzi Coelho Filho; André Schmidt; Ibraim Masciarelli Francisco Pinto; Carlos Eduardo Rochitte; Marcelo Luiz Campos Vieira; Cláudio Tinoco Mesquita; Celso Dario Ramos; José Soares-Junior; Minna Moreira Dias Romano; Wilson Mathias Junior; Marcelo Iório Garcia Junior; Marcelo Westerlund Montera; Marcelo Dantas Tavares de Melo; Sandra Marques E Silva; Pedro Manoel Marques Garibaldi; Aristóteles Comte de Alencar Neto; Renato Delascio Lopes; Diane Xavier de Ávila; Denizar Viana; José Francisco Kerr Saraiva; Manoel Fernandes Canesin; Glaucia Maria Moraes de Oliveira; Evandro Tinoco Mesquita
Journal:  Arq Bras Cardiol       Date:  2021-09       Impact factor: 2.000

3.  Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic Review.

Authors:  Pranav Chandrashekar; Laith Alhuneafat; Meghan Mannello; Lana Al-Rashdan; Morris M Kim; Jason Dungu; Kevin Alexander; Ahmad Masri
Journal:  Circ Genom Precis Med       Date:  2021-08-31

4.  Retinol Binding Protein 4 as a Screening Biomarker for Hereditary TTR Amyloidosis in African American Adults With TTR V142I.

Authors:  Amy R Kontorovich; Noura S Abul-Husn
Journal:  J Card Fail       Date:  2021-05-26       Impact factor: 6.592

5.  Genomic Screening Identifies Individuals at High Risk for Hereditary Transthyretin Amyloidosis.

Authors:  Emily R Soper; Sabrina A Suckiel; Giovanna T Braganza; Amy R Kontorovich; Eimear E Kenny; Noura S Abul-Husn
Journal:  J Pers Med       Date:  2021-01-15

6.  Genomic Screening for Pathogenic Transthyretin Variants Finds Evidence of Underdiagnosed Amyloid Cardiomyopathy From Health Records.

Authors:  Brendan J Carry; Katelyn Young; Samuel Fielden; Melissa A Kelly; Amy C Sturm; J David Avila; Christa L Martin; H Lester Kirchner; Brandon K Fornwalt; Christopher M Haggerty
Journal:  JACC CardioOncol       Date:  2021-10-19

7.  Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK.

Authors:  Julian D Gillmore; Mary M Reilly; Caroline J Coats; Rob Cooper; Helen Cox; Mark R E Coyne; Andrew J Green; Ruth McGowan; William E Moody; Philip N Hawkins
Journal:  Adv Ther       Date:  2022-04-13       Impact factor: 4.070

8.  Established and candidate transthyretin amyloidosis variants identified in the Saudi population by data mining.

Authors:  Mohamed Abouelhoda; Dania Mohty; Islam Alayary; Brian F Meyer; Stefan T Arold; Bahaa M Fadel; Dorota Monies
Journal:  Hum Genomics       Date:  2021-08-11       Impact factor: 4.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.